医学
富维斯特朗
肿瘤科
中期分析
癌症
乳腺癌
内科学
人表皮生长因子受体2
激素受体
转移性乳腺癌
临床试验
雌激素受体
作者
Dennis J. Slamon,Patrick Neven,Stephen Chia,Peter A. Fasching,Michelino De Laurentiis,Seock‐Ah Im,Katarína Petráková,Giulia Bianchi,Francisco J. Esteva,Miguel Martín,Arnd Nusch,Gabe S. Sonke,Luis de la Cruz‐Merino,J. Thaddeus Beck,Xavier Pivot,Manu Sondhi,Yingbo Wang,Arunava Chakravartty,Karen Rodriguez-Lorenc,Tetiana Taran
标识
DOI：10.1056/nejmoa1911149
摘要
In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Here we report the results of a protocol-specified second interim analysis of overall survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
changping
zcl
eric888
LPPQBB
Smar_zcl
小青椒
嘻嘻哈哈
Criminology34
tuanheqi
GingerF
chenqiumu
my
菠菜
star
子车茗
aldehyde
Mic
laber
leaolf
虎皮猫大人
ccm
难过的谷芹
MchemG
皖公网安备34019202002308
